Maria Laura Stromillo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12016702/publications.pdf

Version: 2024-02-01

32	1,928	394421 19	414414 32
papers	citations	h-index	g-index

34	34	34	2854
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. Multiple Sclerosis Journal, 2022, 28, 154-159.	3.0	3
2	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
3	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Molecular Psychiatry, 2022, 27, 1010-1019.	7.9	10
4	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
5	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	6.1	54
6	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 2106-2111.	3.0	30
7	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. Multiple Sclerosis Journal, 2021, 27, 39-51.	3.0	21
8	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
9	Dynamics of pseudoâ€atrophy in RRMS reveals predominant gray matter compartmentalization. Annals of Clinical and Translational Neurology, 2021, 8, 623-630.	3.7	14
10	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
11	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	6.1	184
12	Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 585296.	2.4	4
13	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	2.0	4
14	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. Annals of Neurology, 2020, 88, 93-105.	5.3	79
15	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the â€œbenign statusâ€? A 12-year follow-up study. Multiple Sclerosis and Related Disorders, 2018, 26, 71-73.	2.0	6
16	Vitamin D levels in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Neurological Sciences, 2017, 38, 1333-1336.	1.9	3
17	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Frontiers in Neurology, 2017, 8, 608.	2.4	19
18	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309903.	1.9	162

#	Article	IF	Citations
19	Structural <scp>MRI</scp> correlates of cognitive impairment in patients with multiple sclerosis. Human Brain Mapping, 2016, 37, 1627-1644.	3.6	99
20	Mitochondrial dysfunction in hereditary spastic paraparesis with mutations in DDHD1/SPG28. Journal of the Neurological Sciences, 2016, 362, 287-291.	0.6	24
21	Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. Journal of Neuroscience, 2015, 35, 550-558.	3.6	42
22	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology, 2015, 85, 1722-1723.	1.1	26
23	Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL. Stroke, 2014, 45, 2959-2966.	2.0	16
24	Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis. Neurological Sciences, 2013, 34, 1693-1696.	1.9	6
25	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology, 2013, 80, 2090-2094.	1.1	63
26	Cognitive reserve and cortical atrophy in multiple sclerosis. Neurology, 2013, 80, 1728-1733.	1.1	113
27	Impaired vasoreactivity in mildly disabled CADASIL patients. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 268-274.	1.9	18
28	Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. PLoS ONE, 2012, 7, e44826.	2.5	78
29	Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI. Journal of Neurology, 2011, 258, 2240-2247.	3.6	19
30	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. PLoS ONE, 2011, 6, e19452.	2.5	74
31	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2007, 64, 1157.	4.5	203
32	Systemic Blood Pressure Profile in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke, 2005, 36, 2554-2558.	2.0	37